News
Aytu BioScience to Present at the LD Micro Virtual Investor Conference on Tuesday, December 15 at 2:20pm ET
ENGLEWOOD, CO / December 14, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that management will present at the LD Micro...
Aytu BioScience Increases Previously Announced Bought Deal Offering to $25.0 Million
ENGLEWOOD, CO / December 10, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that, due to demand, the underwriter has agreed to increase...
Aytu BioScience Announces $10.0 Million Bought Deal Offering
ENGLEWOOD, CO / December 10, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that it has entered into an underwriting agreement with H.C....
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company
Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos' established, multi-brand ADHD portfolio, enhancing Aytu's footprint in pediatrics and expanding its presence in adjacent specialty...
Aytu BioScience Announces Fiscal Q1 2021 Net Revenue of $13.5 Million, an Increase of 839% Year-Over-Year
Q1 Consumer Health revenue reaches an all-time high of $7.8 million Live Conference Call and Webcast at 4:30 PM EST ENGLEWOOD, CO / November 12, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing...
Aytu BioScience to Present at the Jefferies 2020 Virtual London Healthcare Conference Wednesday, November 18 at 1:45pm ET
ENGLEWOOD, CO / November 11, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that management will present a corporate...
Aytu BioScience to Report First Quarter Fiscal 2021 Results and Provide Business Update on Thursday, November 12, 2020
Live Conference Call and Webcast at 4:30 PM ET ENGLEWOOD, CO / November 5, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today...
Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year
Company's highest revenue quarter to date is more than 2X its entire fiscal 2019 revenue ENGLEWOOD, CO / October 6, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address...
Aytu BioScience to Report Fourth Quarter and Full Year Fiscal 2020 Results and Provide Business Update on Tuesday, October 6, 2020
Live Conference Call and Webcast at 4:30 PM ET ENGLEWOOD, CO / October 5, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today...
Aytu BioScience to Reschedule Fourth Quarter and FY 2020 Conference Call
ENGLEWOOD, CO / September 23, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that it will reschedule its fourth quarter...